CenterBook Partners LP Decreases Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

CenterBook Partners LP decreased its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 45.3% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 14,025 shares of the medical research company's stock after selling 11,593 shares during the period. CenterBook Partners LP's holdings in Charles River Laboratories International were worth $2,111,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. D1 Capital Partners L.P. purchased a new stake in Charles River Laboratories International during the 4th quarter worth approximately $172,752,000. Assenagon Asset Management S.A. lifted its stake in Charles River Laboratories International by 1,721.1% during the first quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company's stock worth $85,811,000 after purchasing an additional 538,792 shares in the last quarter. Norges Bank purchased a new position in Charles River Laboratories International during the 4th quarter valued at about $98,886,000. Wellington Management Group LLP lifted its position in shares of Charles River Laboratories International by 9.0% during the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after purchasing an additional 335,658 shares in the last quarter. Finally, Nomura Holdings Inc. purchased a new position in shares of Charles River Laboratories International in the fourth quarter valued at approximately $56,820,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on CRL shares. Citigroup upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and upped their price target for the stock from $150.00 to $200.00 in a report on Wednesday, July 9th. Robert W. Baird lifted their price target on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research note on Thursday, May 8th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and lowered their price target for the stock from $188.00 to $182.00 in a report on Friday, May 23rd. Wall Street Zen cut shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Saturday, July 5th. Finally, Evercore ISI increased their target price on Charles River Laboratories International from $170.00 to $180.00 and gave the company an "outperform" rating in a report on Wednesday, July 9th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Charles River Laboratories International has an average rating of "Hold" and a consensus price target of $174.54.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock traded down $2.28 on Friday, hitting $154.42. The stock had a trading volume of 136,798 shares, compared to its average volume of 1,031,650. The stock has a market cap of $7.58 billion, a price-to-earnings ratio of -237.77, a P/E/G ratio of 5.25 and a beta of 1.49. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15. The company's 50 day moving average price is $147.10 and its 200 day moving average price is $151.02.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. The company had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The firm's revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.27 earnings per share. On average, research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president owned 19,513 shares of the company's stock, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).